QLT Unit Pays $112.5M To Resolve Drug Dispute

Law360, New York (February 9, 2007, 12:00 AM EST) -- A U.S. unit of Canada’s generic drug maker QLT Inc. has agreed to shell out $112.5 million to settle a patent infringement lawsuit over its prostate cancer drug Eligard.

QLT USA Inc. said Friday the settlement resolves a lawsuit in the U.S. District Court for the Northern District of Illinois brought by TAP Pharmaceutical Products Inc. and co-plaintiffs Takeda Chemical Industries Ltd. and Wako Pure Chemical Industries Ltd. in 2003, alleging that the unit’s Eligard products violated their patent.

The deal will also resolve QLT’s pending...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.